Akebia Therapeutics, Inc. (AKBA)
Largest Insider Buys in Sector
AKBA Stock Price History Chart
AKBA Stock Performance
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; …
Insider Activity of Akebia Therapeutics, Inc.
Over the last 12 months, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $383,681 worth of Akebia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $422,978 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $344,000 was made by Butler John P. (CEO and President) on 2019‑11‑20.
List of Insider Buy and Sell Transactions, Akebia Therapeutics, Inc.
| 2024-05-13 | Sale | SVP, Chief Operating Officer | 34,840 0.0162% | $1.26 | $43,898 | +3.91% | ||
| 2024-05-13 | Sale | SVP, Chief Legal Officer | 12,016 0.0056% | $1.26 | $15,140 | +3.91% | ||
| 2024-02-29 | Sale | CEO and President | 46,570 0.0249% | $1.58 | $73,581 | -12.74% | ||
| 2024-02-29 | Sale | SVP, Chief Operating Officer | 8,661 0.0046% | $1.58 | $13,684 | -12.74% | ||
| 2024-02-29 | Sale | SVP, Chief Medical Officer | 7,169 0.0038% | $1.58 | $11,327 | -12.74% | ||
| 2024-02-29 | Sale | SVP, Chief Legal Officer | 5,974 0.0032% | $1.58 | $9,439 | -12.74% | ||
| 2024-02-27 | Sale | CEO and President | 37,733 0.0186% | $1.52 | $57,354 | -16.46% | ||
| 2024-02-27 | Sale | SVP, Chief Operating Officer | 10,744 0.0053% | $1.52 | $16,331 | -16.46% | ||
| 2024-02-27 | Sale | SVP, Chief Medical Officer | 8,367 0.0041% | $1.52 | $12,718 | -16.46% | ||
| 2024-02-27 | Sale | SVP, Chief Legal Officer | 7,411 0.0036% | $1.52 | $11,265 | -16.46% | ||
| 2024-02-01 | Sale | CEO and President | 46,489 0.0254% | $1.68 | $78,102 | -18.42% | ||
| 2024-02-01 | Sale | SVP, Chief Medical Officer | 24,311 0.0133% | $1.68 | $40,842 | -18.42% | ||
| 2023-08-25 | Sale | SVP, Chief Medical Officer | 27,000 0.0145% | $1.15 | $31,050 | +9.13% | ||
| 2023-05-25 | Sale | SVP, Chief Operating Officer | 95,478 0.0522% | $1.22 | $116,760 | +3.31% | ||
| 2023-05-25 | Sale | SVP, Chief Legal Officer | 63,186 0.0346% | $1.22 | $77,270 | +3.31% | ||
| 2023-05-16 | Sale | SVP, Chief Medical Officer | 63,567 0.035% | $1.07 | $67,890 | +20.00% | ||
| 2023-05-16 | Sale | SVP, CFO and Treasurer | 63,567 0.035% | $1.07 | $67,890 | +20.00% | ||
| 2023-03-01 | Sale | CEO and President | 91,868 0.0482% | $0.88 | $80,614 | +23.50% | ||
| 2023-03-01 | Sale | SVP, Chief Medical Officer | 14,123 0.0074% | $0.88 | $12,393 | +23.50% | ||
| 2023-03-01 | Sale | SVP, CFO and Treasurer | 7,210 0.0038% | $0.88 | $6,327 | +23.50% |
Insider Historical Profitability
| Butler John P. | CEO and President | 2044580 0.9371% | $1.82 | 6 | 9 | <0.0001% |
| Burke Steven Keith | SVP, Chief Medical Officer | 695840 0.3189% | $1.82 | 1 | 13 | |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651243 0.2985% | $1.82 | 1 | 23 | +3.18% |
| Satter Muneer A | director | 3037042 1.392% | $1.82 | 13 | 0 | <0.0001% |
| Novo A/S | 10 percent owner | 1516387 0.695% | $1.82 | 1 | 0 | +3.18% |
Institutional Investor Ownership
| Alerce Investment Management L P | $24.17M | 6.3 | 13.21M | -18.51% | -$5.49M | 0.28 | |
| The Vanguard Group | $15.05M | 3.93 | 8.23M | +8.13% | +$1.13M | <0.0001 | |
| Acadian Asset Management | $9.71M | 2.53 | 5.31M | -23.22% | -$2.94M | 0.03 | |
| Renaissance Technologies | $6.68M | 1.74 | 3.65M | -23.59% | -$2.06M | 0.01 | |
| Millennium Management LLC | $5.98M | 1.56 | 3.27M | +25.62% | +$1.22M | <0.01 |